India also impacted by Shigellosis, a severe form of bacterial diarrhoea that disproportionately affects children under five ...

GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for the continued development and ...

UK pharma major GSK today revealed that it has licensed its Shigella vaccine candidate, altSonflex1-2-3, to India’s Bharat ...

Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...

Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the ...

LONDON, UK I June 12, 2025 I GSK plc (LSE/NYSE: GSK) announced today that it has licensed its Shigella vaccine candidate, altSonflex1-2-3, to Bharat Biotech ...

Hyderabad: Vaccine maker Bharat Biotech International Limited (BBIL) has in-licensed pharma giant GSK's under development ...

Under terms of the deal, Bharat Biotech will lead late-stage development and scale-up of the altSonflex1-2-3 Shigella vaccine ...

This collaboration reflects Bharat Biotech’s continued commitment to global public health and equitable vaccine access ...

Bharat Biotech has in-licensed GSK's Shigella vaccine candidate, altSonflex1-2-3, aimed at combating Shigellosis in young ...

Bharat Biotech partners with GSK to lead Phase 3 trials and manufacturing of altSonflex1-2-3, targeting deadly Shigella ...

Bharat Biotech and GSK collaborate to advance Shigella vaccine, aiming to combat urgent public health threat globally.